All In Biotech

Drug Trial Radar · NCT07919899

Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation

A Randomized, Open-label, Multiple-dose Phase 3 Study to Evaluate Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation Compared to the Approved Subcutaneous Dupilumab Formulation in Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

May 2, 2028

Study completion Jul 25, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open label, randomized, parallel-group, 2-arm study. The purpose of this study is to measure PK, immunogenicity, safety and, tolerability of dupilumab hyaluronidase coformulation compared with dupilumab approved formulation in male or female participants with moderate-to-severe atopic dermatitis (AD) aged ≥12 years of age. Study details as follows: * The study duration includes screening period up to 4 weeks + treatment period of 20 weeks (± 3 days) and follow-up of 12 weeks (± 7 days). * The number of on-site visits will be 10 and one phone contact will be scheduled (during the follow-up period).

Conditions

  • Dermatitis Atopic

Interventions

  • Dupilumab coformulated with berahyaluronidase alfaDrug

    Pharmaceutical form: solution for injection Route of administration: SC injection

  • DupilumabDrug

    Pharmaceutical form: solution for injection Route of administration: SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ctrough,ss at Week 20Time frame: Week 20

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.